<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Zhu J</submitter><funding>National Cancer Institute</funding><funding>NCI NIH HHS</funding><pagination>4901-4911</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8496948</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>20(10)</volume><pubmed_abstract>Serum-derived extracellular vesicles (EVs) are a promising source of biomarkers; however, major challenges in EV separation and proteomic profiling remain for isolating EVs from a small amount, that is, on the microliter scale, of human serum while minimizing the contamination of blood proteins and lipoprotein particles coeluting in EV preparations. Herein we have developed a column-based CD9-antibody-immobilized high-performance liquid chromatography immunoaffinity chromatography(CD9-HPLC-IAC) technology for EV isolation from a microliter scale of serum for downstream proteomic analysis. The CD9-HPLC-IAC method achieved EV isolation from 40 μL of serum in 30 min with a yield of 8.0 × 10&lt;sup>9&lt;/sup> EVs, where EVs were further processed with a postcolumn cleaning step using the 50 kDa mole</pubmed_abstract><journal>Journal of proteome research</journal><pubmed_title>Column-based Technology for CD9-HPLC Immunoaffinity Isolation of Serum Extracellular Vesicles.</pubmed_title><pmcid>PMC8496948</pmcid><funding_grant_id>R50 CA221808</funding_grant_id><funding_grant_id>R21CA189775</funding_grant_id><funding_grant_id>R01 CA160254</funding_grant_id><funding_grant_id>R21 CA189775</funding_grant_id><pubmed_authors>Zhu J</pubmed_authors><pubmed_authors>Ji X</pubmed_authors><pubmed_authors>Zhang J</pubmed_authors><pubmed_authors>Tan Z</pubmed_authors><pubmed_authors>Lubman DM</pubmed_authors></additional><is_claimable>false</is_claimable><name>Column-based Technology for CD9-HPLC Immunoaffinity Isolation of Serum Extracellular Vesicles.</name><description>Serum-derived extracellular vesicles (EVs) are a promising source of biomarkers; however, major challenges in EV separation and proteomic profiling remain for isolating EVs from a small amount, that is, on the microliter scale, of human serum while minimizing the contamination of blood proteins and lipoprotein particles coeluting in EV preparations. Herein we have developed a column-based CD9-antibody-immobilized high-performance liquid chromatography immunoaffinity chromatography(CD9-HPLC-IAC) technology for EV isolation from a microliter scale of serum for downstream proteomic analysis. The CD9-HPLC-IAC method achieved EV isolation from 40 μL of serum in 30 min with a yield of 8.0 × 10&lt;sup>9&lt;/sup> EVs, where EVs were further processed with a postcolumn cleaning step using the 50 kDa mole</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Oct</publication><modification>2026-06-01T02:23:02.104Z</modification><creation>2025-04-04T10:27:46.342Z</creation></dates><accession>S-EPMC8496948</accession><cross_references><pubmed>34473505</pubmed><doi>10.1021/acs.jproteome.1c00549</doi></cross_references></HashMap>